Protein aggregation and its inhibition in biopharmaceutics.

By Wei Wang. International journal of pharmaceutics, 2005

972 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Protein drug stability: a formulation challenge (2005, background): “Two is a crowd: coping with aggregation During processing and formulation of the drug product, the protein is exposed to conditions that could have significant effects on its chemical and physical stability, and lead to aggregation and ultimately precipitatio”
Aggregation of therapeutic proteins (2017, methodology): “After nucleation, observed aggregation behaviors can often be grouped into one of three categories: 9,20,32 (1) aggregates remain soluble but do not grow substantially; (2) aggregates remain soluble but grow rapidly to high molecular weight (HMW) species; (3) aggregates that begin as dissolved molec”
Properties, Potentials, and Prospects of Antifreeze Proteins (2008, background): “Freezing-induced damage to proteins (Wang, 2005) is also a major stress factor that must be overcome for successful freeze-drying of proteins.”